Scholarlink

Objective <p>To optimize ovulation induction protocols for infertile women with PCOS, ovulation effect and adverse reactions of different doses of letrozole (2.5 vs 5.0&#xa0;mg) combined sequentially HMG therapy were compared&#xa0;in infertility PCOS patients.</p> Methods <p>This open-label randomized controlled trial (RCT) included 174 infertile women aged 18–40 who met the Rotterdam criteria for PCOS at the Wuhan Union Hospital of China from May 2021 to January 2022. They were randomly assigned at a 1:1 ratio to 2.5&#xa0;mg LE or 5.0&#xa0;mg LE on cycle days 3–7 with sequential HMG injections (<i>n</i> = 87 for each).</p> Results <p>There is no difference in ovulation rate between LE (2.5&#xa0;mg) + HMG group and LE (5.0&#xa0;mg) + HMG group in infertile women with PCOS (85.1 vs 85.1%). The ongoing pregnancy rate was no different between the two groups (33.3 vs 25.3%). The percentage of type B endometrial tissues on HCG injection day was higher in the LE (2.5&#xa0;mg) + HMG group (88.5% vs 69.0%). The monofollicular development rate was significantly higher in the LE (2.5&#xa0;mg) + HMG group (67.8% vs. 46.0%).</p> Conclusions <p>Application of 5.0&#xa0;mg LE followed with HMG does not improve the pregnancy rate compared to 2.5&#xa0;mg LE in infertile women with PCOS. An increased dose of LE to 5.0&#xa0;mg may increase the risks of OHSS and multiple pregnancies. Therapy of LE (2.5&#xa0;mg) + HMG may be a more beneficial and optimal treatment protocol for improving endometrial receptivity and promoting mono-follicle development for patients with PCOS.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Human menopausal gonadotropin (HMG) combined different doses of letrozole for treating anovulatory infertility in patients with polycystic ovary syndrome: a randomized controlled trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月7日

查看全文
  • Jingyi Li,
  • Yuan Peng,
  • Xin Dai,
  • Ling Zhang,
  • Xuefeng Long,
  • Xiuping Wang,
  • Weiwei Li,
  • Yuqing Fang,
  • Wenqian Xiong,
  • Yi Liu

摘要

Objective

To optimize ovulation induction protocols for infertile women with PCOS, ovulation effect and adverse reactions of different doses of letrozole (2.5 vs 5.0 mg) combined sequentially HMG therapy were compared in infertility PCOS patients.

Methods

This open-label randomized controlled trial (RCT) included 174 infertile women aged 18–40 who met the Rotterdam criteria for PCOS at the Wuhan Union Hospital of China from May 2021 to January 2022. They were randomly assigned at a 1:1 ratio to 2.5 mg LE or 5.0 mg LE on cycle days 3–7 with sequential HMG injections (n = 87 for each).

Results

There is no difference in ovulation rate between LE (2.5 mg) + HMG group and LE (5.0 mg) + HMG group in infertile women with PCOS (85.1 vs 85.1%). The ongoing pregnancy rate was no different between the two groups (33.3 vs 25.3%). The percentage of type B endometrial tissues on HCG injection day was higher in the LE (2.5 mg) + HMG group (88.5% vs 69.0%). The monofollicular development rate was significantly higher in the LE (2.5 mg) + HMG group (67.8% vs. 46.0%).

Conclusions

Application of 5.0 mg LE followed with HMG does not improve the pregnancy rate compared to 2.5 mg LE in infertile women with PCOS. An increased dose of LE to 5.0 mg may increase the risks of OHSS and multiple pregnancies. Therapy of LE (2.5 mg) + HMG may be a more beneficial and optimal treatment protocol for improving endometrial receptivity and promoting mono-follicle development for patients with PCOS.